Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy

被引:24
作者
Papi, Laura [1 ]
Putignano, Anna Laura [1 ]
Congregati, Caterina [1 ]
Zanna, Ines [2 ]
Sera, Francesco [2 ]
Morrone, Doralba [3 ]
Falchetti, Mario [4 ]
Del Turco, Marco Rosselli [5 ]
Ottini, Laura [4 ]
Palli, Domenico [2 ]
Genuardi, Maurizio [1 ,6 ]
机构
[1] Univ Florence, Med Genet Unit, Dept Clin Physiopathol, I-50139 Florence, Italy
[2] ISPO Sci Inst Tuscany, Mol & Nutr Epidemiol Unit, Florence, Italy
[3] ISPO Sci Inst Tuscany, Senol Unit, Florence, Italy
[4] Univ Roma La Sapienza, Dipartimento Med Sperimentale, Rome, Italy
[5] PRE SA, Prevenz & Salute, Florence, Italy
[6] Fiorgen Fdn Pharmacogen, Florence, Italy
关键词
Hereditary breast/ovarian cancer; Male breast cancer; BRCA1; BRCA2; Founder mutation; MALE BREAST-CANCER; BRCA2; MUTATION; OVARIAN-CANCER; FAMILIES; PREVALENCE; CARRIERS; GENES; RISK; IDENTIFICATION; FREQUENCY;
D O I
10.1007/s10549-008-0190-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Germline mutations in the BRCA1 and BRCA2 tumour-suppressor genes predispose to early-onset breast and ovarian cancer. Although both genes display a highly heterogeneous mutation spectrum, a number of alterations recur in some populations. Only a limited number of founder mutations have been identified in the Italian population so far. Objective To investigate the spectrum of BRCA1/BRCA2 mutations in a set of families originary from the Central-Eastern part of Tuscany and to ascertain the presence of founder effects. We also wanted to approximate the age of the most frequent BRCA1 founder mutation. Results Overall, four distinct BRCA1 mutations accounted for a large fraction (72.7%) of BRCA1-attributable hereditary breast/ovarian cancer in families originary from this area. We identified common haplotypes for two newly recognised recurrent BRCA1 mutations, c.3228_3229delAG and c.3285delA. The c.3228_3229delAG mutation was estimated to have originated about 129 generations ago. Interestingly, male breast cancer cases were present in 3 out of 11 families with the c.3228_3229delAG mutation. Conclusions The observation that a high proportion of families with BRCA1 alterations from Central-Eastern Tuscany harbours a limited number of founder mutations can have significant impact on clinical management of at risk subjects from this area. In addition, the identification of a large set of families carrying an identical mutation that predisposes to breast and ovarian cancer provides unique opportunities to study the effect of other genetic and environmental factors on penetrance and disease phenotype.
引用
收藏
页码:497 / 504
页数:8
相关论文
共 50 条
  • [31] Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history
    Tonin, PN
    Mes-Masson, AM
    Narod, SA
    Ghadirian, P
    Provencher, D
    CLINICAL GENETICS, 1999, 55 (05) : 318 - 324
  • [32] The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population
    Luo, Yu
    Wu, Heming
    Huang, Qingyan
    Rao, Hui
    Yu, Zhikang
    Zhong, Zhixiong
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 2773 - 2786
  • [33] Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center
    Frey, Melissa K.
    Kopparam, Rohini V.
    Zhou, Zhen Ni
    Fields, Jessica C.
    Buskwofie, Ama
    Carlson, Ann D.
    Caputo, Thomas
    Holcomb, Kevin
    Chapman-Davis, Eloise
    CANCER, 2019, 125 (05) : 690 - 697
  • [34] PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland
    Kluska, Anna
    Balabas, Aneta
    Piatkowska, Magdalena
    Czarny, Katarzyna
    Paczkowska, Katarzyna
    Nowakowska, Dorota
    Mikula, Michal
    Ostrowski, Jerzy
    BMC MEDICAL GENOMICS, 2017, 10
  • [35] BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland:: a population-based study
    Rafnar, T
    Benediktsdottir, KR
    Eldon, BJ
    Gestsson, T
    Saemundsson, H
    Olafsson, K
    Salvarsdottir, A
    Steingrimsson, E
    Thorlacius, S
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (18) : 2788 - 2793
  • [36] Frequency of BRCA1 and BRCA2 Mutations in Individuals with Breast and Ovarian Cancer in a Chinese Hakka Population Using Next-Generation Sequencing
    Wu, Heming
    Wang, Qiuming
    Guo, Xuemin
    Liu, Qinghua
    Zhang, Qunji
    Huang, Qingyan
    Yu, Zhikang
    HUMAN HEREDITY, 2020, 84 (4-5) : 160 - 169
  • [37] Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations
    Brohet, Richard M.
    Velthuizen, Maria E.
    Hogervorst, Frans B. L.
    Meijers-Heijboer, Hanne E. J.
    Seynaeve, Caroline
    Collee, Margriet J.
    Verhoef, Senno
    Ausems, Margreet G. E. M.
    Hoogerbrugge, Nicoline
    van Asperen, Christi J.
    Garcia, Encarna Gomez
    Menko, Fred
    Oosterwijk, Jan C.
    Devilee, Peter
    van't Veer, Laura J.
    van Leeuwen, Flora E.
    Easton, Douglas F.
    Rookus, Matti A.
    Antoniou, Antonis C.
    JOURNAL OF MEDICAL GENETICS, 2014, 51 (02) : 98 - 107
  • [38] Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer:: Evidence from 261 cases in Israel, 1976-1999
    Chodick, Gabriel
    Struewing, Jeffery P.
    Ron, Elaine
    Rutter, Joni L.
    Iscovich, Jose
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2008, 51 (02) : 141 - 147
  • [39] Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia
    Ben Ayed-Guerfali, Dorra
    Ben Kridis-Rejab, Wala
    Ammous-Boukhris, Nihel
    Ayadi, Wajdi
    Charfi, Slim
    Khanfir, Afef
    Sellami-Boudawara, Tahia
    Frikha, Mounir
    Daoud, Jamel
    Mokdad-Gargouri, Raja
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [40] BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin
    Infante, M.
    Duran, M.
    Acedo, A.
    Perez-Cabornero, L.
    Sanz, D. J.
    Garcia-Gonzalez, M.
    Beristain, E.
    Esteban-Cardenosa, E.
    de la Hoya, M.
    Teule, A.
    Vega, A.
    Tejada, M-I
    Lastra, E.
    Miner, C.
    Velasco, E. A.
    CLINICAL GENETICS, 2010, 77 (01) : 60 - 69